Humana (NYSE:HUM) Updates FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 16.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.910. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HUM. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. TD Cowen increased their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Wells Fargo & Company cut their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Truist Financial raised their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $296.84.

Humana Stock Performance

Shares of HUM opened at $256.69 on Wednesday. The firm has a market capitalization of $30.91 billion, a P/E ratio of 22.74, a P/E/G ratio of 2.11 and a beta of 0.56. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The stock has a 50 day moving average price of $273.00 and a two-hundred day moving average price of $295.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts forecast that Humana will post 16.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.